纳武利尤单抗在老年转移性透明细胞肾细胞癌患者中的安全性与疗效:NIVOREN GETUG-AFU 26研究分析
该研究基于NIVOREN GETUG-AFU 26 2期试验,评估≥70岁转移性肾细胞癌患者接受纳武利尤单抗的安全性与疗效。≥70岁患者治疗相关3-5级事件发生率更高(24.9% vs 17.9%,p=0.033),但客观缓解率与中位无进展生存期相似,总生存期更短(19.3 vs 26.9个月,HR 1.26),竞争风险模型下不显著。
要点
- ≥70岁患者治疗相关3-5级事件发生率24.9%,高于<70岁患者的17.9%(p=0.033)。
- 两组客观缓解率19.2% vs 22.1%,中位无进展生存期4.5 vs 3.0个月(HR 0.97)相似。
- ≥70岁患者总生存期更短(19.3 vs 26.9个月,HR 1.26),竞争风险模型下不显著。
核心结论
- 纳武利尤单抗在老年患者中显示更高的3/4级治疗相关不良事件,但毒性可控,且疗效持续。
- 老年患者未显示特定的炎症或血管生成循环谱。
研究设计与样本
- GETUG-AFU 26 NIVOREN 2期试验(NCT03013335)分析。
- 转移性肾细胞癌患者在接受至少一种抗血管生成治疗后接受纳武利尤单抗治疗。
- 共720例患者,其中515例<70岁,205例≥70岁。
- 主要终点为≥70岁患者治疗相关3-5级事件发生率。
主要发现
- ≥70岁患者中IMDC poor风险疾病比例21.0% vs 26.9%,肉瘤样成分4.9% vs 9.8%,脑转移5.9% vs 14.7%,既往治疗线数≥2线者54.1% vs 48.5%。
- ≥70岁患者治疗相关3-5级事件发生率24.9% vs 17.9%(p=0.033)。
- 客观缓解率19.2% vs 22.1%,中位无进展生存期4.5 vs 3.0个月(HR 0.97 [95%CI 0.81-1.15])。
- ≥70岁患者总生存期更短(19.3 vs 26.9个月,HR 1.26 [95%CI 1.04-1.51]),竞争风险模型下不显著。
- 仅VCAM-1和4-1BB在≥70岁患者中升高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immune checkpoint inhibitors are standard of care in metastatic renal cell carcinoma but their activity and safety in elderly patients is insufficiently explored. We evaluated outcomes of elderly patients with mRCC treated with nivolumab in the GETUG-AFU 26 NIVOREN phase 2 trial (NCT03013335) and conducted exploratory circulating biomarker analyses. METHODS: Patients with mRCC were treated with nivolumab after at least one antiangiogenic therapy. The main endpoint of this analysis was safety in patients ≥ 70 years old (y.o), as per the rate of treatment-related grade 3-5 events (TRAE). Secondary endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival. Exploration of candidate biomarkers associated with aging included baseline circulating cytokines involved in inflammation, adhesion, immune checkpoints, angiogenesis (IL6, IL7, IL8, BAFF, CXCL13, VCAM-1, 4-1BB, VEGF). RESULTS: Of 720 patients, 515 were < 70 y.o and 205 ≥ 70 y.o. Patients ≥ 70 y.o exhibited numerically less IMDC poor risk disease (21.0% vs 26.9%), sarcomatoid component (4.9% vs 9.8%) or brain metastases (5.9% vs. 14.7%), but more previous treatment lines (≥ 2 in 54.1% vs 48.5%). TRAE were higher in patients ≥ 70 y.o (24.9% vs. 17.9%, p = 0.033). Respective ORR (19.2% vs. 22.1%) and median PFS (4.5 versus 3.0 months, HR 0.97 [95%CI 0.81-1.15]) were similar. Overall survival was shorter in patients ≥ 70 y.o (19.3 versus 26.9 months, HR 1.26 [95%CI 1.04-1.51]), but not significantly in a competitive risk model. Only V-CAM1 and 4-1BB were found to be increased in patients ≥ 70 y.o. CONCLUSIONS: Nivolumab displayed higher grade 3/4 TRAE but manageable toxicity in elderly patients, with sustained activity. Elderly patients did not display specific inflammatory or angiogenic circulating profiles.
引用
- Mourey L, Rainho LT, Dalban C, et al. Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study. Eur J Cancer. 2024. PMID: 38382153. doi:10.1016/j.ejca.2024.113589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。